OneDigital Investment Advisors LLC Cuts Stake in DexCom, Inc. (NASDAQ:DXCM)

OneDigital Investment Advisors LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 58,724 shares of the medical device company's stock after selling 8,375 shares during the quarter. OneDigital Investment Advisors LLC's holdings in DexCom were worth $3,937,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of DXCM. Vanguard Group Inc. grew its stake in shares of DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company's stock worth $6,186,539,000 after acquiring an additional 136,282 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after buying an additional 49,076 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock worth $276,538,000 after buying an additional 353,019 shares during the period. 1832 Asset Management L.P. increased its position in shares of DexCom by 1.1% in the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company's stock valued at $252,906,000 after acquiring an additional 20,400 shares during the period. Finally, Vaughan Nelson Investment Management L.P. raised its stake in DexCom by 14.4% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company's stock worth $183,336,000 after acquiring an additional 203,043 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Sadie Stern sold 426 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company's stock, valued at $5,217,436.65. This represents a 0.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company's stock.

DexCom Trading Up 1.6 %

DexCom stock traded up $1.20 during trading on Friday, reaching $75.88. 6,879,181 shares of the company were exchanged, compared to its average volume of 3,934,491. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock's 50 day simple moving average is $70.03 and its two-hundred day simple moving average is $91.67. The company has a market capitalization of $29.64 billion, a P/E ratio of 45.44, a PEG ratio of 2.22 and a beta of 1.17. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

Analyst Ratings Changes

DXCM has been the topic of a number of research reports. Royal Bank of Canada cut their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. BTIG Research reduced their target price on shares of DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a report on Friday, July 26th. Raymond James cut their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. UBS Group lowered their target price on DexCom from $163.00 to $95.00 and set a "buy" rating on the stock in a research note on Friday, July 26th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.